Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
GJ ConnettNational Institute for Health Research, Southampton Respiratory Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UKAbstract: Lumacaftor-ivacaftor is a combination of two small molecule therapies targeting the basic defect in cystic fi...
Saved in:
Main Author: | Connett GJ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
by: Patrick O. Hanafin, et al.
Published: (2021) -
Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis
by: Stéphanie Bui, et al.
Published: (2021) -
Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021) -
Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022) -
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
by: O’Reilly R, et al.
Published: (2013)